Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | FHIT | P49789 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258668 | 0.89 | TAS1R3 (0.42) | RNASELP2RY1TAS1R3TAS1R1FHIT | |
| SCHEMBL24444145 | 0.89 | POLB (0.46) | POLBRNASELENPP1P2RY1TAS1R3 | |
| SCHEMBL24258656 | 0.89 | TAS1R3 (0.42) | RNASELP2RY1TAS1R3TAS1R1FHIT | |
| SCHEMBL21263835 | 0.88 | POLB (0.40) | POLBRNASELENPP1P2RY1TAS1R3 | |
| SCHEMBL24679905 | 0.84 | RNASEL (0.40) | POLBRNASELENPP1P2RY1TAS1R3 | |
| SCHEMBL24258615 | 0.84 | RNASEL (0.38) | POLBRNASELENPP1P2RY1TAS1R3 | |
| SCHEMBL22219806 | 0.83 | TAS1R3 (0.54) | POLBP2RY1TAS1R3TAS1R1P2RX3 | |
| SCHEMBL21636992 | 0.81 | POLB (0.53) | POLBENPP1P2RY1TAS1R3TAS1R1 | |
| SCHEMBL22352200 | 0.81 | POLB (0.53) | POLBENPP1P2RY1TAS1R3TAS1R1 | |
| SCHEMBL22352087 | 0.81 | POLB (0.53) | POLBENPP1P2RY1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |